TransCode Therapeutics, Inc.TransCode Therapeutics, Inc.TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪6.01 M‬USD
−8.0556USD
‪−18.55 M‬USD
0.00USD
‪17.24 M‬
Beta (1Y)
2.04
Employees (FY)
10
Change (1Y)
−9 −47.37%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−1.85 M‬USD

About TransCode Therapeutics, Inc.


CEO
Thomas A. Fitzgerald
Headquarters
Newton
Founded
2016
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RNAZ is 0.2831 USD — it has decreased by −15.86% in the past 24 hours. Watch TransCode Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TransCode Therapeutics, Inc. stocks are traded under the ticker RNAZ.
RNAZ stock has fallen by −22.33% compared to the previous week, the month change is a −36.81% fall, over the last year TransCode Therapeutics, Inc. has showed a −96.97% decrease.
We've gathered analysts' opinions on TransCode Therapeutics, Inc. future price: according to them, RNAZ price has a max estimate of 3.00 USD and a min estimate of 3.00 USD. Watch RNAZ chart and read a more detailed TransCode Therapeutics, Inc. stock forecast: see what analysts think of TransCode Therapeutics, Inc. and suggest that you do with its stocks.
RNAZ reached its all-time high on Jul 9, 2021 with the price of 5,600.0000 USD, and its all-time low was 0.2160 USD and was reached on Aug 14, 2024. View more price dynamics on RNAZ chart.
See other stocks reaching their highest and lowest prices.
RNAZ stock is 28.37% volatile and has beta coefficient of 2.04. Track TransCode Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TransCode Therapeutics, Inc. there?
Today TransCode Therapeutics, Inc. has the market capitalization of ‪6.01 M‬, it has increased by 11.86% over the last week.
Yes, you can track TransCode Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TransCode Therapeutics, Inc. is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
RNAZ earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.49 USD resulting in a 67.35% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about TransCode Therapeutics, Inc. earnings.
TransCode Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪300.00 K‬ USD. In the next quarter, revenue is expected to reach ‪300.00 K‬ USD.
RNAZ net income for the last quarter is ‪−2.32 M‬ USD, while the quarter before that showed ‪−5.19 M‬ USD of net income which accounts for 55.28% change. Track more TransCode Therapeutics, Inc. financial stats to get the full picture.
No, RNAZ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 10.00 employees. See our rating of the largest employees — is TransCode Therapeutics, Inc. on this list?
Like other stocks, RNAZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TransCode Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TransCode Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TransCode Therapeutics, Inc. stock shows the sell signal. See more of TransCode Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.